Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5125 USD | -0.27% | -96.49% | -96.77% |
Apr. 23 | Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket | MT |
Apr. 22 | Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M | MT |
Financials (USD)
Sales 2024 * | 16.86M | Sales 2025 * | 45.96M | Capitalization | 46.76M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -4M | EV / Sales 2024 * | 2.77 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
-0.04
x | P/E ratio 2025 * |
5.14
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.47% |
Latest transcript on Cidara Therapeutics, Inc.
1 day | -0.27% | ||
1 week | -96.49% | ||
Current month | -97.21% | ||
1 month | -96.70% | ||
3 months | -96.30% | ||
6 months | -96.95% | ||
Current year | -96.77% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
Preetam Shah
DFI | Director of Finance/CFO | 51 | 21-08-31 |
Les Tari
CTO | Chief Tech/Sci/R&D Officer | 57 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 14-03-31 |
Director/Board Member | 69 | 14-03-31 | |
Jeffrey Stein
CEO | Chief Executive Officer | 69 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 10.25 | -0.27% | 95,949 |
24-04-22 | 10.28 | -24.54% | 192,657 |
24-04-19 | 13.62 | -5.68% | 18,245 |
24-04-18 | 14.44 | -0.03% | 13,716 |
24-04-17 | 14.44 | -1.07% | 21,492 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.77% | 46.57M | |
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |
- Stock Market
- Equities
- CDTX Stock